52-Week Highs and Lows, April 8, 2026

14 new highs, 0 new lows.

New 52-Week Highs

ALLO .. $2.82 .. Allogene Therapeutics. Allogeneic CAR-T platform. AlloCAR-T Phase 2 for large B-cell lymphoma advancing toward BLA. Up 214% from its 52W low of $0.86. Cell therapy M&A wave keeps lifting this space.

NECB .. $25.25 .. NorthEast Community Bancorp. Queens-based thrift, converting from mutual to stock form. Clean community bank target in the NYC metro. Fourth week of steady grind higher.

CGEN .. $2.45 .. Compugen. Computational biology platform. COM902 (anti-PVRIG) and COM503 (anti-PVRIG bispecific) in clinical development. Up 103% from the 52W low. Low float, high beta.

CASY .. $762.51 .. Casey's General Stores. Convenience store and fuel chain, 2,900+ locations across the Midwest. Not bio, not bank, just a compounding machine. Up 85% from its 52W low.

RLAY .. $13.55 .. Relay Therapeutics. Dynamo precision medicine platform. PI3K-alpha inhibitor RLY-2608 in Phase 2 for breast cancer. Up 697% from its 52W low of $1.82. Monster runner. Miami Tier 3 name.

SYRE .. $51.26 .. Spyre Therapeutics. Anti-TL1A antibody SPY001 for IBD. Phase 2 data readout coming. Up 376% from the low. Miami Tier 1 name.

PRLD .. $4.82 .. Prelude Therapeutics. CDK9 inhibitor and SMARCA2 degrader in oncology. Hit the high intraday then faded hard to $4.22 close. Classic micro cap volatility. Up 592% from $0.61 low.

MPLT .. $25.79 .. MapLight Therapeutics. CNS muscarinic agonist for schizophrenia and ADP. Two Phase 2 readouts coming Q3. Up 98% from its low. Miami Tier 2 name.

CGON .. $71.90 .. CG Oncology. Intravesical oncolytic virus cretostimogene for bladder cancer. BLA under review. Up 365% from $14.80. Running hard into potential approval.

CARE .. $24.41 .. Carter Bankshares. Virginia community bank. Justice loans cleaned up, Fed membership secured, earnings growing 27% YoY. Sub-$15B, 1.2x book. Classic regional target. Banking scan standout.

ORKA .. $64.61 .. Oruka Therapeutics. Anti-IL-23 for psoriasis, potential once-yearly dosing. Phase 2a data Q2. $480M cash. Up 1,030% from its 52W low of $5.49. Won't stop running.

ETON .. $26.81 .. Eton Pharmaceuticals. Specialty pharma focused on rare disease formulations. Revenue growing, profitable, clean balance sheet. Up 138% from the low. Steady compounder.

ELVN .. $44.67 .. Enliven Therapeutics. Next-gen KIT and BCR-ABL inhibitors for GIST and CML. Phase 2 data for zilurgisertib coming. Up 223% from $13.30. One of the cleanest mid-cap bio setups.

DFTX .. $21.74 .. Aardvark Therapeutics (formerly Diffusion). GLP-1 oral obesity play. ARD-101 Phase 2 data expected 2026. Up 347% from $4.70. Miami Tier 2 name.

Two banking names on the highs list (NECB, CARE). Three Miami names (SYRE T1, MPLT T2, DFTX T2). RLAY is T3. Cell therapy (ALLO) and oncology (CGON, ELVN) driving the bio side. CASY is the lone non-bio, non-bank. 14 highs and zero lows in a single session.